BioSolveIT BioSolveIT
down

About Us

Nice to meet you!

We are BioSolveIT and we visualize drug discovery. Our fast and easy-to-use software enables every chemist to advance their research. Our trusted platforms SeeSAR and infiniSee support you in structure-based and ligand-based drug discovery to inspire you with new, vivid ideas. Perceptive visualization helps you to understand computational results at a glance.
We at BioSolveIT believe in full transparency, and all the science behind our software is published. We are passionate about the needs of our customers and live this through the discovery services we offer. Working together with users in this way helps us stay at the forefront of current research, addressing the questions that chemists are interested in right now.
We develop software that is indispensable to drug discovery and, more importantly, software that is a pleasure to use every day.

What the BioSolveIT World Has to Offer

  • Products:
    Our portfolio of drug discovery software solutions helps you to advance your drug discovery campaigns.
  • Contact research services:
    Let us do the work for you and come up with solutions to your problems.
  • News:
    Recent updates on and around BioSolveIT.
  • BioSolveIT and our distributors:
    BioSolveIT operates on a global level together with local experts to provide tailored solutions and support.
  • Our partners:
    Trusted collaboration partners to advance small molecule drug discovery.

Dr. Christian Lemmen
Co-founder and CEO

Christian received his Ph.D. from the University of Bonn for his work on the FlexS system for the automated superposition of small molecules. In 1999, he began his industry carrier as Senior Research Scientist at the biotech company CombiChem in Palo Alto CA. Later this biotech became part of DuPont Pharmaceuticals and moved to San Francisco. In 2001 he returned to Germany and co-founded BioSolveIT. Dr. Lemmen’s vision is to revolutionize the drug-discovery process by empowering every chemist with the best algorithms wrapped inside the most intuitive user-interfaces.

Board of Directors

Prof. Dr. Dr. Thomas Lengauer

Director Max-Planck Institute for Informatics in Saarbrucken, Germany
Thomas’s background is in Maths (Ph.D. Berlin 1976) and Computer Science (Ph.D, Stanford 1979). His major fields of research are protein structure and function prediction and computational drug screening and design. Thomas has contributed concepts and/or direction to several national research programs on Computational Biology (BMBF and DFG) and is a founding member of the steering boards of the international conference series ISMB and RECOMB. He received numerous awards, among them the Konrad Zuse Medaille and the Karl Heinz Beckurts Preis and is a member of the Leopoldina Presidium.

Prof. Dr. Ralf M. Zimmer

Full Professor Ludwig-Maximilians-University in Munich, Germany
Ralf obtained his Ph.D. in Computer Science and Applied Mathematics from Kiel University. At the German National Research Centre for Information Technology he headed the research group on Algorithmic Structural Genomics. His research interests range from protein sequence analysis, structure prediction, alignments and phylogenies, expression data analysis, metabolic to regulatory networks. Ralf stayed at the National Cancer Institute (NCI/NIH, Washington, DC), and at Stanford University (CA) for research sabbaticals. In 2001, he became Full Professor for Practical Informatics and Bioinformatics at the LMU Munich.

Prof. Dr. Matthias Rarey

Managing Director Center for Bioinformatics, Hamburg University, Germany
Matthias received his PhD from the University of Bonn for his work on protein-ligand docking (FlexX). During research stays with SmithKline Beecham (PA) and Roche Bioscience (CA) he developed the foundations of today’s chemical space technology. In 2002, he became Full Professor for Bioinformatics. His research focusses on the development of novel computational approaches for problems in cheminformatics, structure-based design, and visual chemical analytics. He is Associate Editor of the ACS Journal of Chemical Information and Modeling and elected Vice Chair of the GRC Computer-Aided Drug Design 2021/2023.

Advisory Board

Dr. Torsten Hoffmann

Senior Drug Discovery Consultant
Torsten has over 20 years of international R&D leadership experience gained in a number of high-profile pharma and biotech companies, amongst them Roche, Zealand Pharma, and Taros. He is the inventor of the anti-emetic medicine Akynzeo® that was approved in 2014. At Roche and over the course of 8 years he delivered 50+ new lead series, funneled 30+ small molecules into regulatory tox studies, and brought more than 25+ NCEs into clinical studies.
Torsten has contributed more than 95 publications to the community. His research is focused on small molecules, peptides, and RNAi therapeutics.
Beyond being an outstanding expert in drug candidate design, progression of molecules into clinical development and R&D management, he is a brilliant communicator.

Prof. Dr. Gerhard Klebe

Retired as Full Professor for Pharmaceutical Chemistry at the University of Marburg, Germany
Gerhard’s research goal is the understanding of protein-ligand interactions utilizing chemical synthesis, microcalorimetry, molecular biology, crystallography, and bioinformatics software. In his laboratory, world-renowned tools such as DrugScore and Relibase have been developed. Prior to his academic career he was responsible for molecular modeling and crystallography at BASF-AG in Ludwigshafen, Germany. Gerhard has contributed more than 200 scientific publications.

Dr. Christopher A. Lipinski

Retired as Senior Research Fellow in the Exploratory Medicinal Sciences Department at Pfizer Global Research and Development
Chris received his Ph.D. from the University of California, Berkeley. Thereafter he worked at Pfizer for over three decades and contributed to the discovery of numerous drug candidates. In 1997 he published the well-known Rule of five, that became one of the most cited papers in the field of medicinal chemistry. Chris contributed over 210 publications including 17 patents and been awarded numerous awards for his research achievements.